1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Real-time Estimate Cboe Europe  -  06:12 2022-08-15 am EDT
10994.00 GBX   +2.63%
05:39aFTSE 100 up as AstraZeneca gains offset commodity losses
RE
05:30aAstraZeneca Tops FTSE 100 Risers on Drug Progress
DJ
05:08aEuropean shares edge higher on healthcare lift, weak China data stokes worries
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ASTRAZENECA : Credit Suisse maintains a Buy rating

06/07/2022 | 05:27am EDT

Already positive, the research from Credit Suisse and its analyst Matthew Weston still consider the stock as a Buy opportunity. The target price remains set at GBX 11000.


© MarketScreener with dpa-AFX Analyser 2022
All news about ASTRAZENECA PLC
05:39aFTSE 100 up as AstraZeneca gains offset commodity losses
RE
05:30aAstraZeneca Tops FTSE 100 Risers on Drug Progress
DJ
05:08aEuropean shares edge higher on healthcare lift, weak China data stokes worries
RE
05:08aAstraZeneca, Daiichi Sankyo Say Their Breast Cancer Drug Delayed Disease Progression in..
MT
05:07aFTSE 100 Rises as AstraZeneca Gains on Positive Trial Result
DJ
04:42aFTSE 100 up 0.2%, lifted by Astrazeneca
MS
03:53aLONDON STOCK EXCHANGE : FTSE 100 inches higher as AstraZeneca counters China worries
RE
03:46aEUROPE : European shares edge higher; weak China data stokes worries
RE
02:32aAstraZeneca-Daiichi's breast cancer drug improves survival in study
RE
02:28aEnhertu Significantly Delayed Breast Cancer Progression in Trial, AstraZeneca Says
DJ
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,3x
Yield 2022 2,27%
Capitalization 201 B 201 B -
EV / Sales 2022 5,10x
EV / Sales 2023 4,73x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 129,86 $
Average target price 144,15 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC23.44%201 219
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131